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Abstract
Background. With emerging new therapeutic concepts including renal denervation (RDN), there is a re-
newed interest in resistant hypertension (ResH). Among patients suspected of having ResH, a definitive 
diagnosis needs to be established.
Objectives. This study presents observations from a standardized single-center screening program for RDN 
candidates, including medical therapy modification and reassessment.
Material and methods. All patients referred to our center for RDN underwent a standardized screening 
protocol. Candidates were recruited from among patients receiving no less than 3 antihypertensive drugs, 
including diuretics with office blood pressure (BP) >140/90 mm Hg. The assessment included 2 measurements 
of BP and ambulatory BP monitoring (ABPM). If needed, pharmacotherapy was intensified and the diagnosis 
of ResH was reconfirmed after 6 weeks. If ResH was persistent, patients were hospitalized with repeated 
ABPM on day 4. Further, renal CT-angio was performed and a multidisciplinary team discussed the patients’ 
suitability for RDN.
Results. A total of 87 patients with a ResH diagnosis were referred for RDN. Mean office BP was 159/92 
(±7.0/6.5) mm Hg and mean ABPM was 154/90 (±9.0/4.8) mm Hg. The initial medication included angio-
tensin convertase inhibitors (ACE-I, 78%), angiotensin receptor blockers (12%), β-blockers (85%), calcium 
channel blockers (36%), and diuretics (93%). During the 18 months of the RDN program, 5 patients underwent 
RDN and 2 further had ineligible renal anatomy. A new diagnosis of secondary hypertension was made 
in 21 patients. However, in 59 patients, BP control was achieved after optimization of medical therapy, with 
a mean ABPM of 124/74 mm Hg. The final treatment included ACE-I (100%), β-blockers (92%), indapamide 
(94%), amlodipine (72%), and spironolactone (61%). Medication in most of these patients (88%) included 
single-pill triple combination (52.5%) or double combination (35.6%).
Conclusions. Patients with elevated BP screened for RDN require a rigorous diagnostic workup. Up to 2/3 
of patients can be managed with strict pharmacotherapy compliance and pharmaceutical intensification, in-
cluding single-pill combinations and improved drug compliance. Hasty use of RDN may be a result of poor drug 
optimization and/or compliance. It does remain a viable treatment option in thoroughly vetted ResH patients.
Key words: compliance, arterial hypertension, resistant hypertension, renal artery denervation
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Arterial hypertension (HA) remains a  major public 
health concern with substantial morbidity and mortal-
ity, affecting nearly 25% of all adults in the industrialized 
world. More specifically, the national health registry data 
in Poland suggest that approx. 10.5 million people suffer 
from HA, accounting for approx. 32% of the adult popula-
tion.1 Over the past decades, a great deal of research and 
literature has focused on HA leading to a general con-
sensus about the pathomechanisms, pharmacotherapy 
and other treatment modalities; however, there remains 
a subset of patients that do not benefit from the standard 
treatment algorithm. These patients are thought to suf-
fer from resistant hypertension (ResH), which is defined 
as blood pressure (BP) that remains above the goal in spite 
of optimal doses of 3 antihypertensive agents of different 
classes, ideally including a diuretic.2 However, in situations 
where elevated office BP is due to white-coat hypertension, 
improper BP measurement or medication non-compliance, 
patients are considered not to have true ResH, but rather 
so-called pseudo-ResH.3
In the case of true ResH, a failure of pharmacotherapy 
leads to more invasive methods of treatment, which are 
based conceptually on the role of the autonomic nervous 
system in the pathogenesis of HA. Initially, invasive tech-
niques involved surgical sympathectomy of abdominal 
organs,4 which is usually successful in anti-hypertensive 
effects but often results in unbearable gastrointestinal 
distress. Thus, a consensus was reached that renal artery 
denervation (RDN), a more selective procedure, may be 
an option for patients with ResH. The authors of the larg-
est clinical trials examining RDN – HTN 1,5 HTN 26 and 
HTN 37 – established strict inclusion criteria and proce-
dural guidelines for the consideration of RDN. Accord-
ing to the practice-based guidelines, patients suspected 
of ResH undergo serial consultations along with confirma-
tory testing. Due to the complicated screening and veri-
fication of clinical suspicions of RDN, there needs to be 
a consensus on the diagnosis and final qualification for 
RDN therapy. In this paper, the authors seek to analyze 
the causes of disqualifications from RDN in patients with 
a suspected diagnosis of ResH.
Material and methods
We conducted a prospective study, enrolling 
87 consecutive patients with a preliminary di-
agnosis of ResH who were hospitalized in either 
the cardiology or nephrology wards at the Medi-
cal University of Lodz, Poland. For the purposes 
of the study, ResH was defined as BP that re-
mained above the goal in spite of optimal doses 
of 3 antihypertensive agents of different classes, 
1 ideally being a diuretic, in accordance with 
the most updated guidelines set forth by the Eu-
ropean Society of Hypertension and the European 
Society of Cardiology.2 Participation in the study required 
informed consent, which outlined all the study procedures 
and potential side effects. The study protocol was broken 
down into multiple phases: a preliminary phase to confirm 
the diagnosis of true ResH and a confirmation/hospital 
phase. The preliminary phase included screening for true 
ResH, composed of a detailed medical history and HA 
analysis, outlined in Fig. 1.
Preliminary phase observations helped to exclude pa-
tients with a diagnosis of secondary HA or those with 
an increased vascular risk (i.e., abdominal aortic aneurysm 
or atherosclerosis obliterans) in invasive RDN. The patient 
interview was focused on a detailed history of the patient’s 
HA and past medical and pharmacotherapy. A small subset 
of patients was found to be mismanaged according to treat-
ment guidelines and a definitive diagnosis of ResH could 
not be made. In these cases, the pharmacotherapy was op-
timized and the preliminary stage of the study was repeat-
ed after 6 weeks to assess for true ResH. When a diagnosis 
of ResH was confirmed during the initial or reassessment 
visit (after pharmacotherapy optimization), a patient was 
enrolled in the study and admitted to the hospital.
The second phase of the study, considered the confirma-
tion/hospital stage, is outlined in Fig. 2. A continuation 
of pharmacotherapy along with routine BP monitoring 
was followed by blood tests to further exclude any other 
causes of HA or risks in undergoing RDN.
After all inclusion criteria were met, the patients were 
screened and qualified to undergo the RDN procedure. 
The SymplicityTM renal denervation system (Medtronic, 
Dublin, Ireland) was used to carry out the RDN procedure. 
Each RDN procedure was conducted by a properly trained 
operator –  a  cardiologist, experienced in  percutaneous 
coronary angioplasty procedures and supported by a high-
ly qualified licensed technician sent by the manufacturer. 
Post-procedure hospitalization lasted an average of 3 days. 
Ambulatory BP monitoring (ABPM) and a blood test were 
conducted on the last day of hospitalization just before dis-
charge, and again at 6 months (±2 weeks) and 12 months 
(±4 weeks). The approval of the Medical University of Lodz 
Bioethics Committee/Institutional Review Board was ob-
tained for this study.
Fig. 1. Preliminary phase testing
2 independent oce measurements of arterial blood pressure
calculation of estimated glomerular ltration rate (eGFR)
24 h blood pressure monitoring (ABPM)
• positive qualication when systolic BP was ≥140 mm Hg 
   or the diastolic BP was ≥90 mm Hg
• eGFR score >30mL/min/1.73 m2 was an inclusion criterion 
• positive qualication to screening for RDN when mean systolic BP 
  was >135 and/or mean diastolic BP was >85 mm Hg
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Statistical analysis
The quantitative data was compared to a standardized 
bell curve with the Kolmogorov–Smirnov test (Lilliefors 
modification). When the data was compatible to normal 
distribution, a mean and standard deviation were used 
(mean ±SD). A variance analysis for dependent samples 
was performed. The calculations were carried out on Med-
Calc Statistical Software v. 17.11.5 (MedCalc Software 
bvba, Ostend, Belgium).
Results
A total of 87 patients (33 female, 54 male) were enrolled 
in  the study. The demographics are shown in Table 1. 
The mean office BP measurement in the study group was 
159/92 (±8.7/6.5) mm Hg and the mean ABPM measure-
ment was 154/90 (±9/4.8) mm Hg. During the 18 months 
of  enrollment, only 5  patients fully satisfied 
the inclusion criteria and were qualified to un-
dergo RDN. The primary choice for vascular 
access was the right femoral artery, and no local 
complications were noted after the procedure.
All the patients who underwent the RDN pro-
cedure were followed up at 6 and 12 months, 
in accordance with the protocol. A modification 
of pharmacotherapy was required in 1 patient 
– a reduction of β-adrenolytic due to asymptom-
atic bradycardia. The treatment of other patients 
was not altered during the observation time. Of-
fice BP and ABPM measurements revealed a re-
duction of overall BP as compared to the initial 
measurements at the time of enrollment. Blood 
pressure measurements from consecutive visits 
are shown in Table 2.
The patients that underwent RDN all had sat-
isfactory primary renal function with estimated 
glomerular filtration rates (eGFR) >60 mL/min/1.73 m2. 
There was no significant deterioration of renal function 
Fig. 2. Hospital procedures of study protocol
continuation of pharmacotherapy
double BP measurement bedside, repeated 3 times a day
blood sampling: morphology, metabolic panel, liver function
computer tomography angiography of abdominal aorta and renal arteries
consultation with endocrinologists and hypertensiologists
exclusion of primary hyperaldosteronism
• assessment of electrolytes in blood and urine,
• primary aldosterone concentration measurement,
• aldosterone concentration measurement after captopril inhibition test
• in the absence of anatomic aberrations that could interrupt RDN
Table 1. Demographic and clinical characteristics of the study population
Parameter Mean ±SD
Age [years] 63.58 ±10.01
Gender (female/male) 33 (37.9%)/54 (62.1%)
Diabetes mellitus type 2 22 (25.3%)
Coronary artery disease 24 (27.6%)
Hypercholesterolemia 23 (26.4%)
Atrial fibrillation 11 (12.6%)
History of stroke 8 (9.2%)
eGFR (MDRD) [mL/min/1.73 m2] 73.67 ±23.11
Creatinine [mg/dL] 1.06 ±0.29
Time of HA therapy [years] 15.01 ±5.99
SD – standard deviation; eGFR – estimated glomerular filtration rate; 
MDRD – eGFR estimation formula; HA – arterial hypertension.
Table 2. Office BP measurements and ABPM measurements during the follow-up period in patients that underwent RDN





Mean office BP measurements
Systolic BP 158.80 ±6.40 134.70 ±4.40 130.50 ±1.32 <0.001
Diastolic BP 88.30 ±4.56 85.10 ±4.55 81.60 ±6.19 0.14
ABPM results
24-hour systolic BP 141.40 ±4.83 127.60 ±8.38 130.60 ±6.39 0.015
24-hour diastolic BP 82.60 ±4.34 70.80 ±7.82 71.20 ±6.30 0.026
Systolic BP – day 145.00 ±5.24 132.20 ±11.67 135.40 ±6.19 0.017
Diastolic BP – day 86.20 ±5.26 75.80 ±10.71 75.60 ±7.50 0.053
Systolic BP – night 132.00 ±4.36 120.20 ±5.50 123.00 ±4.18 0.049
Diastolic BP – night 75.80 ±6.91 61.60 ±7.86 65.40 ±5.90 0.088
BP – blood pressure; M0, M6, M12 – consecutive follow-up visits at the end of hospitalization, after 6 and 12 months post hospitalization; SD – standard 
deviation; ABPM – ambulatory blood pressure monitoring.
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in the follow-up period. The eGFR values based on the Mod-
ification of Diet in Renal Disease (MDRD) Study Equation 
are shown in Table 3.
There were 82 patients that did not qualify for RDN pro-
cedure, all with a diagnosis of elevated BP despite optimal 
pharmacotherapy. The mean office BP measurements and 
mean ABPM scores for this group are shown in Table 4. For 
the patients who were disqualified from RDN, the reasons 
have been outlined in Table 5.
Secondary hypertension due to various etiologies was 
diagnosed in 21 (25.6%) of disqualified patients. The most 
frequent cause of secondary hypertension was a signifi-
cant stenosis of at least 1 of the renal arteries (12 cases 
(14.6%)). These patients were advised to continue with 
a diagnostic workup and treatment with vascular sur-
gery. Seven patients (8.5%) were found to have primary 
hyperaldosteronism and 2 (2.4%) were discovered to have 
an active adrenal aldosterone-secreting adenoma and were 
referred to endocrinologists. Another 2 patients (2.4%) 
had an abnormal renal artery diameters and kidneys with 
multiple vascular supplies.
Another 59 patients (72%) were diagnosed with pseu-
do-ResH, defined as an initial diagnosis of ResH but with 
suboptimal pharmacotherapy or patient noncompliance. 
At the end of the screening phase, optimization of therapy 
and counseling on compliance lead to this group achieving 
a satisfactory BP and disqualification from RDN. All the pa-
tients diagnosed with pseudo-ResH had initial BP measure-
ments that could qualify them for RDN. The mean office BP 
and ABPM scores in the screening phase and after final effec-
tive pharmacotherapy administration are shown in Table 6.
In this pseudo-resistant group, a satisfactory BP was 
achieved at various points in the screening process. In all 
cases, pharmacotherapy was optimized during the ini-
tial screening visit and BP measurements were repeated 
at 6 weeks. The majority of patients (36) achieved satisfac-
tory BP measurements at this point. In 23 of these cases, 
ResH was the working diagnosis until the first hospital-
ization. Despite some patients having BP measurements 
that qualified for RDN during the initial screening, not all 
of them were treated with diuretics. The pharmacotherapy 
regimen of the screening failure group on presentation 
and final pharmacotherapy regimen are shown in Fig. 3,4.
In most cases, the addition of hypertensive therapy was 
based on single-pill combinations with 2 or 3 substances. 
In 31 patients (52.5%), we chose a triple combination pill of per-
indopril, amlodipine and indapamide. In 21 patients (35.6%) 
a combination pill of perindopril and amlodipine was utilized.
In summary, an initial diagnosis of ResH was ruled out 
due to the discovery of reversible causes of high BP in 82 
cases (94%). Improper treatment or noncompliance issues 
were the cause of this in 59 of the patients (68%).
Table 3. The eGFR values of the patients who underwent renal 









1 105.37 100.88 117.45
2 85.01 89.29 87.81
3 77.50 72.69 83.93
4 85.64 91.10 87.75
5 80.81 76.17 75.08
eGFR – estimated glomerular filtration rate; eGFR 0, 6, 12 – values 
of estimated glomerular filtration rate during the first visit and during 
follow-up visits in the 6th and 12th month.
Table 4. Office BP measurements and ABPM measurements during 
the follow-up period in patients disqualified from RDN
Parameter Mean +SD




24-hour systolic BP 153.95 ±8.89
24-hour diastolic BP 89.86 ±4.56
Systolic BP – day 158.45 ±8.89
Diastolic BP – day 91.44 ±6.15
Systolic BP – night 149.38 ±8.96
Diastolic BP – night 88.27 ±7.06
RDN – renal denervation; BP – blood pressure; SD – standard deviation; 
ABPM – ambulatory blood pressure monitoring.
Table 5. Main causes of disqualification from renal denervation during 
screening (number of patients)
• Non-optimal pharmacotherapy (59)
• Secondary hypertension (21)
– significant stenosis in renal artery (12)
– primary hyperaldosteronism (7)
– active adrenal adenoma (2)
• Renal artery anatomy improper to RDN procedure (2) 
Table 6. Office BP measurements and ABPM measurements including 








Mean office BP measurements
Systolic BP 158.6 ±8.0 125.30 ±5.81
<0.001
Diastolic BP 93.4 ±5.4 81.70 ±4.45
ABPM results
24-hour systolic BP 153.3 ±7.9 123.9 ±1.9
<0.001
24-hour diastolic BP 89.9 ±4.7 74.4 ±1.9
Systolic BP – day 157.8 ±7.9 129.6 ±2.5
Diastolic BP – day 91.6 ±6.5 79.6 ±2.5
Systolic BP – night 148.7 ±8.0 118.3 ±3.3
Systolic BP – night 88.2 ±6.9 69.3 ±3.0
BP – blood pressure; SD – standard deviation; ABPM – ambulatory blood 
pressure monitoring.
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Discussion
Resistant hypertension presents a clinical challenge of-
ten requiring an arduous diagnostic workup, pharmaco-
vigilance, optimization of anti-hypertensive medications, 
and a detailed medical history to rule out non-compliance. 
Our study, to the best of our knowledge, is the first to an-
alyze a population of patients initially presenting with 
a presumed diagnosis of ResH that in actuality suffered 
from uncontrolled hypertension caused by suboptimal 
pharmacotherapy or poor compliance issues.
Symplicity HTN-1 was the  first clinical trial examin-
ing percutaneous transcatheter RDN in  the  treatment 
of ResH.4 The study consisted of a cohort of 50 patients 
who underwent RDN; a sustainable BP lowering effect was 
observed during consecutive follow-up visits at 1, 3, 6, 9, and 
12 months. The cohort was then increased to 153 patients 
and the follow-up period was extended to 3 years.8 The hy-
potensive effect of RDN was still present 36 months from 
the date of the procedure. Blood pressure measurements 
were on average 32 mm Hg lower for systolic BP and 14.4 mm 
Hg lower for diastolic BP as compared to the measurements 
at the initial screening. It was observed that the percentage 
of local femoral site complications was not any higher than 
those in similar procedures such as coronary angiography. 
Renal denervation did not have a negative impact on renal 
function. Other studies have also reported similar obser-
vations.9 Nevertheless, RDN is an invasive procedure and 
should only be performed in definitive cases of ResH.
There should be no ambiguity in the qualification of pa-
tients with ResH for RDN procedures. The results of our 
study show that ineffective medical therapy with 3 or more 
hypotensive drugs (including diuretics) is not enough to es-
tablish a definitive diagnosis. High BP in an outpatient set-
ting may be a symptom of various disorders or of psychoso-
matic causes such as “white coat hypertension”, which may 
be defined as persistently elevated BP (≥140/90 mm Hg) 
“in the presence of a healthcare worker, particularly a phy-
sician” in patients not taking medication, with an average 
awake ABPM < 135/85 mm Hg.10 To obtain unadulterated 
objective measurements of BP, 24-hour ABPM is required.11 
When suboptimal BP control is confirmed, it still requires 
exclusion of potentially reversible causes of HA. In our study 
25.6% of the RDN disqualifications were caused by potential-
ly reversible or secondary causes of hypertension, which gen-
erally have a prevalence of 5–10% in hypertensive patients.12 
Renal diseases such as renal artery disease, glomerular and 
tubular diseases are responsible for almost 50% of cases 
of secondary hypertension.12 It is also important to note 
that diseases with significant deterioration of glomerular 
filtration excluded most of these patients from the RDN 
procedure in our study. Patients with serious renal artery 
stenosis need a more significant diagnostic workup due 
to stimulation of the renin-angiotensin-aldosterone system.
As demonstrated by our study and the literature, exclusion 
of secondary causes of HA is necessary. The most common 
and available methods to exclude this diagnosis are imaging 
techniques, most commonly renal Doppler ultrasonography.13 
An RDN screening requires more specific methods that can 
in addition visualize the aorta and femoral arteries. Computed 
tomography (CT) with contrast is more appropriate, provid-
ing precise vascular imaging and providing visualization 
of the kidneys and adrenal glands to rule out any possible pa-
thologies. Appreciation of the quantity and diameter of renal 
arteries is also necessary in preparing for RDN. In addition, 
renal and adrenal gland anomalies may be responsible for high 
BP which may be confirmed through imaging techniques.
Another significant cause of HA are pathologies result-
ing in the disruption of normal hormonal activity.14 In our 
study, we excluded 2 patients from RDN due to the pres-
ence of adrenal tumors discovered using CT. Detailed ex-
amination and diagnostic workup confirmed the hormonal, 
aldosterone-exerting activity of these tumors. Other patients 
with endocrine-disrupting properties had either primary 
hypertrophy of the renal cortex or primary hyperaldoste-
ronism, diagnosed in 7 subjects in this group. Computed 
tomography was not useful in these cases, but, as the litera-
ture suggests, renal scintigraphy is more specific.15 Renal 
artery anatomy is another important issue that can influence 
the course, effectiveness and safety of the renal denerva-
tion procedure. Short, bendy and narrow vessels should be 
noted and may exclude patients from RDN.16 Furthermore, 
there is a group of patients with more than 1 artery supplying 
blood to the kidney. The general prevalence of this anomaly 
is seen in up to 28%17 or 34%13 of patients with HA. In our 
study, we disqualified 2 patients from undergoing RDN due 
to the presence of multiple renal arteries in 1 kidney.
Fig. 4. Final pharmacotherapy in patients with pseudoresistant 
hypertension






























ACI β-adrenolics indapamide amlodipine spironolactone
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The  most common reason for disqualification from 
RDN in our study was inappropriate or suboptimal medi-
cal therapy which was identified in the initial screening 
phase of  the  study. In 72% of  the cases, modifications 
of pharmacotherapy led to optimized BP control. A de-
tailed medical history interview often revealed multiple 
therapeutic modifications leading to  non-compliance. 
Numerous studies have been performed over the past de-
cades discussing patient attitudes and compliance. It has 
been reported that satisfactory compliance is seen in only 
about 50% of cases. Partial compliance is seen in approx. 
30–40% of patients, and 5–10% admit that they take their 
drugs selectively or do not take them at all.18 Achievement 
of optimal BP control by adding another drug as opposed 
to increasing the dose of the current regimen is a strat-
egy confirmed by numerous studies.19 On the other hand, 
the effectiveness of therapy increases when the number 
of pills is reduced.20,21 The only way to reconcile these 
issues is single-pill combination therapy.19 In our study, 
patients disqualified from RDN during the initial screen-
ing phase due to potential drug compliance issues were 
ultimately transitioned to a single-pill triple combina-
tion (52.5%) or single-pill double combination (35.6%). 
In 28% of our cases, optimal BP control was achieved with 
the initiation of new pharmacotherapy, but only during 
the hospitalization period. These findings affirmed that 
drug compliance was the most important cause of false 
positive reports of ResH.
Conclusions
Renal artery denervation is  an  innovative method 
of treatment for ResH but remains debated, and its in-
dication is decreasing. Improvements in technical skill 
and greater availability of devices for performing RDN 
are necessary. Additional studies must also be performed 
to further assess the benefits of the procedure.
The presence of uncontrolled high BP does not automati-
cally warrant a diagnosis of ResH, regardless of duration. 
Such cases always require thorough diagnostic testing 
to exclude secondary causes of hypertension. It is the up 
to  the  due diligence of  healthcare workers to  provide 
a conscientious choice of pharmacotherapy, taking into 
account the patient’s capabilities and needs, to allow for 
good compliance.
Analyzing the methodology of our study, we hypoth-
esize that the best way to achieve compliance is single-
pill combinations of anti-hypertensives, but larger studies 
focused on the issues of compliance are required to verify 
this assumption.
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